

This SOP represents practice maximums.

CATEGORY		EMR	EMT	AEMT		Р	
Analgesics				ALWII	•	•	
Analycolog	Acetaminophen		•	•	•	•	
	Nonsteroidal anti-inflammatory			•			
	Opiates and related narcotics			•			
	Dissociative analgesics						
	Ketamine 0.5 mg/kg or less IV/IN/IM				•	•	Added IM as a route of administration 10-4-18
	Retainine 0.5 mg/kg of less tv/fiv/fivi						Added this as a foute of administration 10-4-16
Anesthetics/Sedatives							
Anesthetics/Sedatives	Taniaal/Otia/Ossular			•	•	•	
	Topical/Otic/Occular		•				
	Inhaled-self administered		•	•	•	•	
	Local (infiltration)			•	•	•	
	General - initiate					•	
	General - maintenance intubated patient				•	•	Added as a category and maintained at the I level, MDC 10-4-18
	Sedation for the violent/aggressive patient				•	•	Added as a category and maintained at the I level, MDC 10-4-18
	Antipsychotics				•		
	Benzodiazepines (for sedation)				•	•	
Anticonvulsants				•	•	•	
Glucose Altering Agents							
	Glucose Elevating Agents		•	•	•	•	
	Glucose Lowering Agents				•	•	
	_						
Antidotes							
	Anticholinergic Antagonists				•	•	
	, and a superior and germene					_	
	Anticholenesterase Antagonists	•		•	•		
	7 interiorioriostorado 7 intagornoto						
	Benzodiazepine Antagonists						
	Derizodiazopino / tritagornoto						
	Narcotic Antagonists	•					
	Narcotic Artagoriists						
	Nondepolarizing Muscle Relaxant						
	Antagonist						
	Antagonist						
	Beta/Calcium Channel Blocker Antidote				•	•	
	Deta/Calcium Channel Blocker Antidote					•	
	Triougha Antidonasa ( O )						
	Tricyclic Antidepressant Overdose				•	•	
	Cyanide Antidote				•	•	

"Investigational medications and procedures which have been reviewed and approved by an Institutional Review Board (IRB) will be considered to be approved by the Medical Direction Committee solely within the context of the approved study. Investigators involved in IRB approved research are asked to present their study plans to the MDC for informational purposes so that the committee can maintain an awareness of on-going pre-hospital research in the Commonwealth. Those who desire to conduct non-IRB reviewed pilot projects, demonstration projects, or research are asked to present those proposals to the MDC prior to their implementation for review and approval by the MDC."



This SOP represents practice maximums.

OATE OODY		EMP		4 = 14 =			
CATEGORY	D. II	EMR	EMT	AEMT		Р	
	Cholinesterase Reactivator	•	•	•	•	•	
Antihistamines & Combination	ns		•	•	•	•	
Biologicals							
	Immune Serums					•	
	Antibiotics		•	•	•	•	
Blood/Blood products							
-	Initiate					•	
	Maintain				•	•	
Blood Modifiers							
	Anticoagulants				•	•	
	Antiplatelet Agents		•	•	•	•	
	- map mare a significant			_	_	_	
	Hemostatic Agents		•	•	•	•	
	Tromostatio / tgome						
	Thrombolytics					•	
	Trii omboly a oo						
	Anti-fibrinolytics (eg tranexamic acid)			•	•	•	Added at the AEMT level, MDC 10-4-18
	7 tha horniory and (eg tranoxamine and)						Added at the AEMT lovel, MBC 10 4 10
Cardiovascular Agents							
Odralovascular Agents	Alpha Adrenergic Blockers				•	•	
	Alpha Adrenergic blockers						
	Adrenergic Stimulants				•	•	
	Auteriergic Stirriularits						
	A satismula, dia satism				•	•	
	Antiarrhythmics						
	Data Adragania Diadaga				•		
	Beta Adrenergic Blockers				•	•	
	Calcium Channel Blockers				•	•	
	B) (1						
	Diuretics				•	•	
	Inotropic Agents				•	•	
	Vasodilatory Agents		•	•	•	•	
	Vasopressors				•	•	

"Investigational medications and procedures which have been reviewed and approved by an Institutional Review Board (IRB) will be considered to be approved by the Medical Direction Committee solely within the context of the approved study. Investigators involved in IRB approved research are asked to present their study plans to the MDC for informational purposes so that the committee can maintain an awareness of on-going pre-hospital research in the Commonwealth. Those who desire to conduct non-IRB reviewed pilot projects, demonstration projects, or research are asked to present those proposals to the MDC prior to their imple mentation for review and approval by the MDC."



This SOP represents practice maximums.

inephrine for allergic reaction inephrine administration systems for ergic reaction (See note below)  tipsychotic  amins  nerals - start at a health care facility elts - start at a health care facility ectrolytes Solutions - started at a health	EMR	• • • • • • • • • • • • • • • • • • •	AEMT  •	•	P • • • • • • • • • • • • • • • • • • •	Approved by MDC 1-3-19  Sedatives - Benzodiazepines removed from this section, MDC 10-
inephrine administration systems for ergic reaction (See note below)  tipsychotic  amins  nerals - start at a health care facility  lts - start at a health care facility				•	•	
inephrine administration systems for ergic reaction (See note below)  tipsychotic  amins  nerals - start at a health care facility  lts - start at a health care facility				•	•	
ergic reaction (See note below)  tipsychotic  amins  nerals - start at a health care facility  lts - start at a health care facility		•	•	•		
amins nerals - start at a health care facility lts - start at a health care facility				•		
amins nerals - start at a health care facility llts - start at a health care facility				•	•	
amins nerals - start at a health care facility llts - start at a health care facility				•	•	Sedatives - Benzodiazepines removed from this section, MDC 10-
amins nerals - start at a health care facility llts - start at a health care facility						Sedatives - Benzodiazepines removed from this section, MDC 10-
nerals - start at a health care facility lts - start at a health care facility	Ş					<u>'</u>
nerals - start at a health care facility lts - start at a health care facility	Ç					
nerals - start at a health care facility lts - start at a health care facility	9					
lts - start at a health care facility	9					
lts - start at a health care facility		See secti	on: Intraver	ous Fluic	le	
		1	I IIIII avei	l laic	l	
culvivies solulions - stanteu at a nealth - I						
re facility						
pertonic Saine						
	•	•	•			
liox				•	•	
OTC			•	•	•	
tidiarrheals		•	•	•	•	
tiemetics			•		•	
2 Blockers		•	•	•	•	
			•	•	•	
pitocin, octreotide, prostaglandins					•	
						EMT may transport patient with IV fluids not requiring titration or
						adjustment, and without additives including electrolytes (e.g.
otonic		•	•	•	•	potassium, magnesium)
potonic		•	•	•	•	
pertonic				•	•	
		М	I/M	I/M	I/M	
ttion to poor	gen ox acids OTC diarrheals emetics EMT SL/PO route only Blockers ticosteroids, Mineralocorticoids er Hormones bitocin, octreotide, prostaglandins	gen ox  acids  OTC  diarrheals  emetics  EMT SL/PO route only  Blockers  ticosteroids, Mineralocorticoids er Hormones oitocin, octreotide, prostaglandins  onic otonic ertonic  M = Maintenance I = Initiate stalloid, +/- Dextrose/Lactate	gen ox  dacids  OTC  diarrheals  emetics  EMT SL/PO route only Blockers  ticosteroids, Mineralocorticoids er Hormones oitocin, octreotide, prostaglandins  onic otonic ertonic  M = Maintenance I = Initiate stalloid, +/- Dextrose/Lactate  M	gen ox  diarrheals  emetics  EMT SL/PO route only Blockers  ticosteroids, Mineralocorticoids er Hormones oitocin, octreotide, prostaglandins  onic  otonic  M = Maintenance I = Initiate stalloid, +/- Dextrose/Lactate  M   I/M	gen ox  Gacids  OTC  Giarrheals  emetics  EMT SL/PO route only Blockers  ticosteroids, Mineralocorticoids er Hormones oitocin, octreotide, prostaglandins  onic  M = Maintenance I = Initiate stalloid, +/- Dextrose/Lactate  M   I/M   I/M   I/M	gen  ox  acids  OTC  diarrheals  emetics  EMT SL/PO route only  Blockers  ticosteroids, Mineralocorticoids er Hormones oitocin, octreotide, prostaglandins  onic  onic

"Investigational medications and procedures which have been reviewed and approved by an Institutional Review Board (IRB) will be considered to be approved by the Medical Direction Committee solely within the context of the approved study. Investigators involved in IRB approved research are asked to present their study plans to the MDC for informational purposes so that the committee can maintain an awareness of on-going prehospital research in the Commonwealth. Those who desire to conduct non-IRB reviewed pilot projects, demonstration projects, or research are asked to present those proposals to the MDC prior to their imple mentation for review and approval by the MDC."



This SOP represents practice maximums.

OATE CODY		EMB		4 F14 F			1
CATEGORY		EMR	EMT	AEMT		Р	
	with Multi=vitamins		M	M	М	M	
	with Thiamine		M	M	М	M	
Neuromuscular Blockers							
Respiratory	Anticholinergics		•	•	•	•	
	Sympathomimetics						
	Beta agonists		•	•	•	•	
	Epinephrine (nebulized)				•	•	
Dosage and Concentration Calculation				•	•	•	
M = Maintenance							
I = Initiate							
1 - Illidate	Note: EMT's may administer medications						
	within their scope of practice in addition to						
	assistance in administration of those						
	medications. EMT's may access a drug kit						
	to access those medications.						
	Note: Med-Math skills including dosage						
	calculations and measurement of						
	medication to be administered are outside						
	EMT scope of practice. EMT's may draw						
	epinephrine from vials or ampules for the						
	treatment of acute allergic reactions using						
	devices/systems using syringes with						
	mechanical limiters or color-coded or other						
	clearly marked indicators to allow accurate						
	dose measurement.						
	EMT may transport patient with IV fluids not						
	requiring titration or adjustment, and without						
	additives including electrolytes (e.g.						
	potassium, magnesium)						
	potacolam, magnoolam)						<u>,                                      </u>

"Investigational medications and procedures which have been reviewed and approved by an Institutional Review Board (IRB) will be considered to be approved by the Medical Direction Committee solely within the context of the approved study. Investigators involved in IRB approved research are asked to present their study plans to the MDC for informational purposes so that the committee can maintain an awareness of on-going pre-nospital research in the Commonwealth. Those who desire to conduct non-IRB reviewed pilot projects, demonstration projects, or research are asked to present those proposals to the MDC prior to their implementation for review and approval by the MDC."